2-(4-nitrophenyl)-3H-benzoimidazole-5-carboxylic acid phenylamide | 820242-65-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-(4-nitrophenyl)-3H-benzoimidazole-5-carboxylic acid phenylamide
• 英文别名: 1H-Benzimidazole-5-carboxamide, 2-(4-nitrophenyl)-N-phenyl-；2-(4-nitrophenyl)-N-phenyl-3H-benzimidazole-5-carboxamide
• CAS: 820242-65-7
• 化学式: C₂₀H₁₄N₄O₃
• 分子量: 358.356
• InChiKey: ZCEKJMJJYXCQSP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Benzoimidazole derivatives as anticancer agents
  申请人：CENTRE LEON BERARD

  公开号：US11384081B2

  公开（公告）日：2022-07-12

  The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing said compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.

  本公开涉及作为抗癌药物的苯并咪唑衍生物，以及含有上述化合物的药物组合物。这些化合物首先能抑制 MAP 激酶 Erk 的蛋白/蛋白相互作用，从而抑制增殖，其次能诱导人类癌细胞株凋亡。
• BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS
  申请人：Centre Leon Berard

  公开号：EP3515904A1

  公开（公告）日：2019-07-31
• Benzoimidazole Derivatives As Anticancer Agents
  申请人：CENTRE LEON BERARD

  公开号：US20220348587A1

  公开（公告）日：2022-11-03

  The disclosure relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing the compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.
• [EN] BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS<br/>[FR] DÉRIVÉS DE BENZOIMIDAZOLE EN TANT QU'AGENTS ANTICANCÉREUX
  申请人：CENTRE LEON BERARD

  公开号：WO2018054989A1

  公开（公告）日：2018-03-29

  The invention relates to benzoimidazole derivatives, acting as anticancer drugs, as well as pharmaceutical composition containing said compounds. These compounds are able to firstly inhibit the protein/protein interactions of the MAP Kinase Erk, leading to inhibition of proliferation and secondly to induce apoptosis in human cancer cell lines.